Our Mission
Our goal is to develop collaborative, impactful research that will lead to improved brain health for the people of Cleveland, and for all.
NervGen celebrates successful Phase1b/2a trial
NervGen, founded by the late Jerry Silver, recently completed a clinical trial on their novel compound NVG-291 for the pharmacologic treatment of chronic spinal cord injury. The results showed lasting improvement in limb and bladder function and quality of life in patients treated with the novel compound.
The Latest
We hope to see you at the Breakthroughs in Cancer Neurosciences event on October 5th. Hear how we are combining the forces of two outstanding research programs, the Case Comprehensive Cancer Center and the Department of Neurosciences, to better understand the challenges of neuro-oncology from diagnosing and treating tumors of the brain and spinal cord to addressing nervous system issues caused by other types of cancer.